A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis
This study is designed to provide efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis (SPMS) and to obtain regulatory approval to make BAF312 available for clinical use worldwide.
Neuroscience - Multiple Sclerosis
James Bowen, MD
- Adult men and women aged 18 to 60 years with a diagnosis of MS with relapsing-remitting MS (RRMS).
- Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS or a history of cancer are excluded
Beena Gangadharan and Amanda Brown